
The CHMP has recommended expanding dolutegravir to term newborns weighing at least 2 kg and dolutegravir/lamivudine to children as young as 3 months, and European Commission decisions are expected in Q1 2027.
Jason C. Gallagher, PharmD describes how healthcare practitioners can counsel patients on the recent increases in antibiotic-resistant sexually transmitted infections.
Contagion® speaks with Jason C. Gallagher, PharmD, FCCP, BCPS, Clinical Professor at the Temple University School of Pharmacy and a Clinical Pharmacy Specialist in Infectious Diseases at Temple University Hospital about how healthcare practitioners can counsel patients on the recent increases in antibiotic-resistant sexually transmitted infections.





